NCT00254046View on ClinicalTrials.gov

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

PHASE3CompletedINTERVENTIONAL

Enrollment

616

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

July 31, 2008

Conditions

HIV

Interventions

DRUG

TMC125

2 X100 mg tablets b.i.d.96 weeks

DRUG

Placebo

2 tablets b.i.d.96 weeks

Trial Locations (55)

Unknown

Little Rock

Beverly Hills

Los Angeles

San Diego

San Francisco

New Haven

Washington D.C.

Fort Lauderdale

Miami

North Miami Beach

Pensacola

Safety Harbor

Tampa

Vero Beach

Atlanta

Macon

Wichita

Boston

Newark

Santa Fe

New York

The Bronx

Huntersville

Winston-Salem

Portland

Philadelphia

Austin

Dallas

Galveston

Houston

Longview

Annandale

Buenos Aires

Córdoba

Neuquén

San Juan Bautista

Curitiba

Rio de Janeiro

Salvador

São Paulo

Providencia

Santiago

San José

Bordeaux

Lyon

Marseille

Paris

Guadalajara

Mex Ctity

Mexico City

Panama City

San Juan

San Juan Pr

Bangkok

Khon Kaen

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00254046 - TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options. | Biotech Hunter | Biotech Hunter